Malaria infects hundreds of millions and claims over 600,000 lives annually. Despite decades of global research, vaccine development faced persistent challenges due to ineffective adjuvants.
The breakthrough came when Novavax leveraged QS-21 sourced from DesertKing to create a novel adjuvant that amplifies vaccine-induced immune responses. Powered by this QS-21-based adjuvant system, Oxford University and the Serum Institute of India (SII) successfully developed the R21/Matrix-M™ vaccine, released in 2023. This innovation has now received WHO validation and official recommendation.
Commencing distribution in May 2024, SII delivers doses at under $4 each. Over the next three years, SII will supply 50-60 million annual doses to malaria-endemic regions in Africa, substantially mitigating global disease burden.
As DesertKing’s Exclusive Authorized Distributor for QS-21 in China, Vuroyal Pharmaceuticals enables vaccine innovators through adjuvant supply and technical support. For partnership opportunities:
📞 +86-527-88881019
✉️ qs21@vuroyal.com